Department of Rehabilitation Medicine, University of Washington, Seattle, WA, USA Endo Pharmaceuticals, Chadds Ford, PA, USA.
Pain. 2013 Apr;154(4):534-538. doi: 10.1016/j.pain.2012.12.017. Epub 2012 Dec 28.
Assay sensitivity remains a significant issue in pain clinical trials. One possible method for increasing assay sensitivity for detecting changes in pain intensity is to increase the reliability of pain intensity assessment by increasing the number of intensity ratings obtained, and combining these ratings into composite scores. The current study performed secondary analyses from a published clinical trial to test this possibility. The reliability and assay sensitivity pain intensity scores made up of 1 to 9 24-hour pain intensity recall ratings were compared. Although the reliability of the outcome measures improved as the number of items increased, this increase in reliability was not associated with an increase in assay sensitivity. A single 24-hour recall rating was about as valid (sensitive) for detecting treatment effects as composite scores made up of 2 to 9 different ratings. If this finding replicates in other pain populations, it has significant implications for the design and conduct of pain clinical trials. Specifically, it suggests the possibility that assessment burden (and associated costs and problems related to missing data) might be greatly reduced by specifying a single recall rating as the primary outcome variable. Research is needed to explore this possibility further.
在疼痛临床试验中,检测灵敏度仍然是一个重要问题。一种提高检测疼痛强度变化的检测灵敏度的可能方法是通过增加获得的强度评估次数来提高疼痛强度评估的可靠性,并将这些评估综合为综合评分。本研究对已发表的临床试验进行了二次分析,以检验这种可能性。比较了由 1 到 9 个 24 小时疼痛强度回忆评估组成的可靠性和检测灵敏度疼痛强度评分。虽然随着项目数量的增加,测量结果的可靠性有所提高,但这种可靠性的提高与检测灵敏度的提高无关。单次 24 小时回忆评估与由 2 到 9 个不同评估组成的综合评分一样,对检测治疗效果具有同样的有效性(敏感性)。如果这一发现可以在其他疼痛人群中得到复制,那么这对疼痛临床试验的设计和实施具有重要意义。具体而言,它表明,通过将单次回忆评估指定为主要结局变量,评估负担(以及与数据缺失相关的成本和问题)可能会大大降低。需要进一步研究来探索这种可能性。